Get startedLog in
    Picture of ExpreS2ion Biotech Holding AB logo

    EXPRS2 — ExpreS2ion Biotech Holding AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: ExpreS2ion Awarded SEK 2.7 Mln For Continued Development Of Two Malaria Vaccine Candidates

    Picture of ExpreS2ion Biotech Holding AB logoExpreS2ion Biotech Holding AB
    12/12/2019 14:35
    Dec 12 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * EXPRES2ION HAS BEEN AWARDED SEK 2.7 MILLION FOR CONTINUED
DEVELOPMENT OF TWO MALARIA VACCINE CANDIDATES
    * ULTIMATE GOAL OF PROJECT IS TO CREATE A NEXT GENERATION
BLOOD-STAGE COMBINATION VACCINE

Source text for Eikon:  ID:nWkr260KZ7 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

    Recent news on ExpreS2ion Biotech Holding AB

    See all news